Immunome, Inc. Accumulated Other Comprehensive Income
Immunome, Inc. (IMNM) had Accumulated Other Comprehensive Income of -$333.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-11
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$333.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $0.00.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $0.00.
- 2025-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$24.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$333.00K 10-Q · filed 2026-08-11 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-11 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$24.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | -$3.00K 10-Q · filed 2025-05-12 |
| 2024-12-31 | $57.00K 10-K · filed 2026-03-03 |
| 2024-09-30 | $70.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $2.00K 10-Q · filed 2024-08-12 |
| 2024-03-31 | $4.00K 10-Q · filed 2024-05-14 |
| 2023-12-31 | $22.00K 10-K · filed 2025-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |